title: Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea.
abstract: BACKGROUND
  Essential thrombocythemia (ET) is classified as a Philadelphia chromosome-negative classic myeloproliferative neoplasm. ET is a clonal stem cell disorder that is often associated with JAK2 mutations and shares phenotypic and pathogenetic similarities with other myeloproliferative neoplasms. Hemorrhagic complications and arterial and venous thrombosis are common in patients with ET. The aim of this retrospective analysis was to assess the cumulative incidence rate and risk factors for thrombohemorrhagic events in patients with ET based on a multicenter study in Korea.
  
  
  METHODS
  A total of 239 patients with ET, from February 1995 to April 2011, were retrospectively analyzed from 4 Korean academic institutions. Data were collected through the review of medical records, and vascular events were confirmed by diagnostic procedures for establishing thrombosis and hemorrhagic complications.
  
  
  RESULTS
  Of the patients (median age, 61 years; median follow-up, 51.8 months), 32 (13.4%) experienced thrombohemorrhagic complications. The 10-year cumulative incidence rate showed a 20.6% incidence of thrombohemorrhagic events. In univariate analysis, the presence of JAK2 mutations, high-risk group, previous thrombohemorrhagic events, and >60 years old were shown to have higher incidences of vascular events than any other factors. In multivariate analysis, previous thrombotic events and JAK2 mutations were independent risk factors for vascular events (hazard ratio, 2.907 [95% CI, 1.142-7.406], P =.025; and 4.146 [95% CI 1.227-14.018], P = 0.022).
  
  
  CONCLUSIONS
  Previous thrombotic history and the JAK2 V617F mutation were associated with a higher 10-year cumulative incidence rate of thrombohemorrhagic events.
authors.affiliation: Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, South Korea.
authors.forename: Ho Sup
authors.initials: HS
authors.lastname: Lee
authors.forename: Lee Chun
authors.initials: LC
authors.lastname: Park
authors.forename: Eun Mi
authors.initials: EM
authors.lastname: Lee
authors.forename: Shin Jun
authors.initials: SJ
authors.lastname: Lee
authors.forename: Seong Hoon
authors.initials: SH
authors.lastname: Shin
authors.forename: Hana
authors.initials: H
authors.lastname: Im
authors.forename: Kil Min
authors.initials: KM
authors.lastname: Do
authors.forename: Eeon Jin
authors.initials: EJ
authors.lastname: Kim
authors.forename: Byeong Jin
authors.initials: BJ
authors.lastname: Ye
authors.forename: Moo Kon
authors.initials: MK
authors.lastname: Song
authors.forename: Sung-Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Sang Min
authors.initials: SM
authors.lastname: Lee
authors.forename: Won Sik
authors.initials: WS
authors.lastname: Lee
authors.forename: Yang Soo
authors.initials: YS
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019943:Amino Acid Substitution; D044466:Asian People / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006470:Hemorrhage / Q000208:ethnology / Q000209:etiology*; D006801:Humans; D015994:Incidence; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009154:Mutation; D056910:Republic of Korea / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors; D013920:Thrombocythemia, Essential / Q000150:complications* / Q000235:genetics*; D013927:Thrombosis / Q000208:ethnology / Q000209:etiology*; D013997:Time Factors; D055815:Young Adult
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2